Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors

• ClinicalTrials.gov Identifier: NCT02285101
• Recruitment Status: Completed
• First Posted: November 6, 2014
• Last Update Posted: April 24, 2020
• Sponsor: Bio-Cancer Treatment International Limited
• Collaborator: Oncotherapeutics
• Information provided by (Responsible Party): Bio-Cancer Treatment International Limited

Tracking Information

• First Submitted Date: October 23, 2014
• First Posted Date: November 6, 2014
• Last Update Posted Date: April 24, 2020
• Study Start Date: November 2014
• Actual Primary Completion Date: February 2019 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: November 4, 2014)

• Number of patients undergoing adverse events (AEs) or serious adverse events (SAEs) [ Time Frame: at least 13 weeks ]
• Optimal Biological Dose [ Time Frame: 13 weeks ]
  The optimal biological dose (OBD) of PEG-BCT-100 will be calculated based on the pharmacodynamics (PD) endpoint of plasma arginine depletion relative to plasma pharmacokinetics (PK) of PEG-BCT-100

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: November 4, 2014)

• Maximum Tolerated Dose and Dosing Schedule [ Time Frame: 4 weeks of treatment ]
• Overall response [ Time Frame: 13 weeks ]
  Evaluate objective tumor responses by RECIST (Response Evaluation Criteria In Solid Tumors)
• Pharmacokinetics (PK)-PEG-BCT-100 concentration [ Time Frame: 13 weeks ]
  Determine the dose-related peak to trough concentrations of plasma PEG-BCT-100 over time
• Pharmacodynamics (PD) [ Time Frame: 13 weeks ]
  To determine the magnitude of plasma arginine depletion (AD) relative to the dose of PEG-BCT-100
• PK-PEG-BCT-100 plasma clearance [ Time Frame: 13 weeks ]
  the plasma clearance of PEG-BCT-100
• PD-duration of AD [ Time Frame: 13 weeks ]
  the time and duration of effective AD assessed by plasma arginine <8 µM relative to the plasma peak and time to clearance over the range of PEG-BCT-100 doses
• PD-relationship between AD and PEG-BCT-100 dose [ Time Frame: 13 weeks ]
  the temporal and quantitative relationships of depleted plasma arginine to dose and plasma concentrations of PEG-BCT-100
• PD-relationship between PEG-BCT-100 dose and tumor markers [ Time Frame: 13 weeks ]
  the temporal and quantitative relationships of depleted plasma arginine to dose and plasma concentrations of PEG-BCT-100; and, The relationship of PEG-BCT-100 dose and its resultant effective AD to changes in AFP/PSA and/or tumor symptoms and measurements.

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors
• Official Title: Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety and PK/PD
• Brief Summary: The goal of this clinical research study is to evaluate the safety of PEG-BCT- 100 given as an infusion to treat patients who bear advanced solid tumors that are dependent on arginine (melanoma, renal cell carcinoma, prostate cancer and hepatocellular carcinoma), and who have progressed after receiving approved or established therapies. This is a Phase 1 study; PEG-BCT-100 is an enzyme that degrades arginine and is an investigational drug.

Detailed Description

This is a phase 1, multiple sites, open label and non-randomized study to evaluate the safety of PEG-BCT-100. Patient enrollment and sample size will follow a classical 3 + 3 dose-escalation design. The study will enroll a maximum of 36 patients. Cohorts of 3 patients will receive an initial single dose of PEG-BCT-100 beginning at 0.5 mg/kg. Single dose safety parameters including hematology and chemistry laboratory profiles will be monitored for 3 weeks. Patients not demonstrating a dose-limiting toxicity (DLT) following the single dose may then receive two additional doses of PEG-BCT-100 at the same dose level on Day 22 and Day 29. After these 2 additional doses, patients will undergo a full tumor and safety assessment after Day 29. Patients whose cancer is stable or responding may then receive weekly doses of PEG-BCT- 100 until disease progression. Dose escalations are planned for the next cohorts of 3 patients, which will be enrolled after Day 22 of the previous cohort, assuming that no single dose DLTs were reported. Each cohort of 3 patients may begin weekly administration if there is no DLTs by Day 22, and if the previous and lower dose cohort has successfully passed Week 4 of the study (doses on Days 1, and 22 + one week).

As of the beginning of 2018, an additional 22 patients will include only malignant melanoma patients. All newly enrolled patients will be enrolled at the dose level of Cohort Four (2.7 mg/kg) of PEG-BCT-100.

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: Non-Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Melanoma
• Prostate Adenocarcinoma

Intervention

Biological: PEG-BCT-100

Other Name: pegylated recombinant human arginase

Study Arms

• Experimental: Cohort 1
  PEG-BCT-100 at 0.5 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 0.5 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 0.5 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 0.5 mg/kg until disease progression at the discretion of the investigator.
  Intervention: Biological: PEG-BCT-100
• Experimental: Cohort 2
  PEG-BCT-100 at 1.0 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.0 mg/kg on days 22 (week4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.0 mg/kg until disease progression at the discretion of the investigator.
  Intervention: Biological: PEG-BCT-100
• Experimental: Cohort 3
  PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.7 mg/kg until disease progression at the discretion of the investigator.
  Intervention: Biological: PEG-BCT-100
• Experimental: Cohort 4
  PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 2.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 2.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 2.7 mg/kg until disease progression at the discretion of the investigator.
  Intervention: Biological: PEG-BCT-100
• Experimental: Cohort 5
  PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 4.0 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 4.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 4.0 mg/kg until disease progression at the discretion of the investigator.
  Intervention: Biological: PEG-BCT-100
• Experimental: Cohort 6
  PEG-BCT-100 at a dose to be determined administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT-100 will be administered at at a dose to be determined on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at at a dose to be determined. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at at a dose to be determined until disease progression at the discretion of the investigator.
  Intervention: Biological: PEG-BCT-100

• Publications *: De Santo C, Cheng P, Beggs A, Egan S, Bessudo A, Mussai F. Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma. J Hematol Oncol. 2018 May 18;11(1):68. doi: 10.1186/s13045-018-0612-6.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: April 22, 2020): 23
• Original Estimated Enrollment (submitted: November 4, 2014): 36
• Actual Study Completion Date: February 2019
• Actual Primary Completion Date: February 2019 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Confirmed diagnosis of Stage IIIb/IV malignant melanoma or castration resistant adenocarcinoma of prostate (CRPC).
• Advanced cancer not candidate for treatment with modality or agents that are approved or have established efficacy. Candidates who cannot tolerate standard treatment or whose cancers have progressed on current standard of care.
• Males or females 18 years-old and above.
• Ability to understand and willingness to provide written informed consent;
• Karnofsky performance status (see Appendix 13.3) of 80% or above and expected survival of more than 12 weeks.
• Negative urine pregnancy test, if female, and willingness to use an effective method of contraception during the entire study period whether the patient is male or female.

Exclusion Criteria:

• Has received cancer treatment, e.g. chemotherapy, targeted biologic or enzymes, either approved or investigational, within 4 weeks prior to the start of the PEG-BCT-100;
• Advancing liver failure indicated by uncontrolled ascites, pleural effusions, or encephalopathy.
• Child-Pugh score of B and C (see Appendix 13.4).
• Significant hepatic, renal or bone marrow dysfunction indicated by: total bilirubin >2.0 mg/dL, evidence of bile duct obstruction, serum albumin <2.5 g/dL, serum ALT or AST >2.5 x upper limit of normal, serum creatinine ≥1.5 mg/dL, ANC ≥1.5 x 109/L, platelets <100 x 109/L, or INR >2.0.
• Significant cardiac or pulmonary disease defined by New York Heart Association (NYHA) Class III or IV (see Appendix 13.5), left ventricular ejection fraction (LVEF) lower than institutional normal limits by echo or MUGA, history of myocardial infarction within the past 6 months, significant unstable arrhythmia or evidence of ischemia on ECG.
• Pregnant or nursing women. NOTE: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• Significant active infection including HIV requiring oral or parenteral anti-infective therapies.
• Use of investigational drug(s) within 4 weeks of enrollment.
• Prior treatment with arginine depleting agent.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02285101
• Other Study ID Numbers: BCT-100-005
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: Bio-Cancer Treatment International Limited
• Study Sponsor: Bio-Cancer Treatment International Limited
• Collaborators: Oncotherapeutics

Investigators

• Principal Investigator: Alberto Bessudo, MD; California Cancer Associates For Research and Excellence, cCARE
• Principal Investigator: Steven O'Day, MD; John Wayne Cancer Institute

• PRS Account: Bio-Cancer Treatment International Limited
• Verification Date: April 2020